Goldman Sachs notes that Vera Therapeutics (VERA) shares are down 18% and underperforming the biotech group today following earnings results from Otsuka that included a comment on potential at-home administration of sibeprenlimab with a pre-filled syringe. However, the firm views this as “overdone” and an “overreaction” given that the disclosure largely aligns with expected competitive developments in the IgA nephropathy space. The firm, which notes that Vera is conducting the Phase 3 ORIGIN 3 study of 150 mg atacicept in patients with IgAN while utilizing at-home administration with once-weekly dosing, reiterates a Buy rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics weakness on Otsuka plans ‘makes no sense,’ says Wells Fargo
- Vera Therapeutics initiated with an Outperform at Wolfe Research
- 3 Best Stocks to Buy Now, 1/29/2025, According to Top Analysts
- Vera Therapeutics initiated with a Buy at Goldman Sachs
- 3 Best Stocks to Buy Now, 1/17/2025, According to Top Analysts
Questions or Comments about the article? Write to editor@tipranks.com